| Document |
Document Title |
|
WO/2021/249505A1 |
The present invention provides an insulin degludec derivative and a preparation method therefor. Specifically, the present invention provides a fusion protein comprising a green fluorescent protein folding unit and an insulin degludec pr...
|
|
WO/2021/250468A2 |
The present disclosure relates to the fields of chemistry and medicine, more particularly to processes for making 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2 -cyclopropyl-1-(3 -fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-...
|
|
WO/2021/252669A1 |
Provided are methods related to treating congenital adrenal hyperplasia in a subject in need thereof comprising administering to the subject a compound of Formula (I): [INSERT FORMULA] (I), or a pharmaceutically acceptable salt thereof.
|
|
WO/2021/252844A1 |
Systems, devices, compositions, and methods for treating diabetes are provided, including co-administering insulin and glucagon to a patient. Data collected from studies conducted to observe co-administration of insulin and glucagon to a...
|
|
WO/2021/249402A1 |
The present invention involves effects of a cell-free fat liquid extract on macrophage polarization modulation and disease treatment. Specifically, provided by the present invention are uses of a cell-free fat extract, said uses being (i...
|
|
WO/2021/249534A1 |
Disclosed are a phthalazinone compound, and a preparation method therefor and the medical use thereof. In particular, disclosed are a compound as represented by formula (I), and a pharmacodynamically acceptable salt, and the use of the c...
|
|
WO/2021/244606A1 |
Provided herein is a method of treating, preventing, or ameliorating one or more symptoms of a glucokinase-mediated disorder, disease, or condition in a hepatically impaired subject with a glucokinase activator (GKA), for example, dorzag...
|
|
WO/2021/244582A1 |
The present application provides a novel thyroid hormone β receptor agonist having better activity, selectivity or safety and represented by formula (I), and use thereof in preventing or treating a disease related to the β receptor ago...
|
|
WO/2021/243646A1 |
Provided herein is a method of treating, preventing, or ameliorating one or more symptoms of a glucokinase-mediated disorder, disease, or condition in a hepatically impaired subject with a glucokinase activator (GKA), for example, dorzag...
|
|
WO/2021/240006A1 |
The invention relates to a composition in the form of an injectable aqueous solution, the pH of which is from 3.0 to 4.4, including at least a rapid-acting insulin analog and at least one glucagon suppressor with prandial action. In an e...
|
|
WO/2021/237321A1 |
The present invention patent application pertains to the medical sector and comprises a long-lasting reabsorbable subcutaneous implant with sustained release of a pre-concentrated pharmacologically active substance in a polymer for the t...
|
|
WO/2021/240356A1 |
Described herein are pyrrolo{2,3-d}pyrimidine derivatives, their use as Janus Kinase (JAK) inhibitors, and pharmaceutical compositions containing them.
|
|
WO/2021/239115A1 |
Provided are a GLP-1/glucagon dual agonist and the use thereof. The GLP-1/glucagon dual agonist is a GLP-1 mutant protein, which can bind and activate the activities of the class B G-protein-coupled receptor GLP-1R and the glucagon recep...
|
|
WO/2021/242297A1 |
Pharmaceutical compositions comprising azelastine or a pharmaceutically acceptable salt of azelastine and alprazolam are disclosed. Methods of using the pharmaceutical compositions for treating perimenopausal or menopausal patients, such...
|
|
WO/2021/240004A1 |
[0001] The invention relates to a composition in the form of an injectable aqueous solution, the pH of which is from 3.0 to 4.4, in particular from 3.6 to 4.4, including at least a rapid-acting insulin analog and at least one glucagon su...
|
|
WO/2021/235372A1 |
The present invention provides a solubilizer for producing a solid dispersion. This solubilizer comprises a copolymer of 2-methacryloyloxyethyl phosphorylcholine and a methacrylic acid ester, said copolymer having a repeating unit repres...
|
|
WO/2021/229835A1 |
This liquid pharmaceutical preparation contains Component 1 and Component 2, and has a pH greater than 5.0 and less than or equal to 6.0. Component 1) teriparatide or a salt thereof; Component 2) a component that satisfies all of conditi...
|
|
WO/2021/231199A1 |
The present disclosure provides a nasal delivery device with a device body that includes a trigger end and an outlet end. The nasal delivery device also includes a trigger assembly coupled to the trigger end of the device body, a drug co...
|
|
WO/2021/222997A1 |
The present invention relates to a composition of beta-glucans and silymarin (Milk thistle) and one or more bifidogenic prebiotics, for use as a nutritional or nutraceutical supplement, or as a prebiotic, with the aim of modulating the n...
|
|
WO/2021/218687A1 |
The use of a muscle stem cell in the preparation of a drug for preventing, alleviating and treating metabolic disorders, and a pharmaceutical composition for humans and animals, wherein the pharmaceutical composition comprises the muscle...
|
|
WO/2021/213538A1 |
Provided is a compound or a pharmaceutically acceptable salt, isomer, prodrug, polymorph, or solvate thereof, and a preparation method therefor and use thereof. The compound is used as a GnRHR antagonist in a calcium flux detection exper...
|
|
WO/2021/209562A1 |
The present invention relates to a liposomal composition for use as a medicament. In particular, the present invention relates to a liposomal composition for use in prevention or early treatment of pathogenic infection. More specifically...
|
|
WO/2021/208290A1 |
Provided in the present invention is use of GPHB5 glycoprotein hormone for preparing a medicament for reducing obesity and lipid or a medicament for treating glucose intolerance, insulin resistance or diabetes in obese populations. The u...
|
|
WO/2021/207759A1 |
Kisspeptin 1 receptor (KISS1R) is a G protein-coupled receptor which binds the 54-AA peptide hormone kisspeptin (metastin). TAK-448 is a potent Kisspeptin 1 receptor (KISS1R, or GPR54) agonist. Kisspeptin and KISS1R in the brain play key...
|
|
WO/2021/191366A1 |
The present invention relates to salts of budesonide 21-phosphate with β2 adrenergic agonists, preferably with formoterol, pharmaceutical compositions containing the same and the use thereof in the treatment of respiratory inflammatory ...
|
|
WO/2021/194013A1 |
The present invention relates to a vaccine composition for eliminating boar taint, comprising a recombinant protein in which a cholera toxin B subunit (CTB) and a gonadotropin-releasing hormone (GnRH) are fused. More specifically, the pr...
|
|
WO/2021/194906A1 |
Methods of preventing, treating, managing or controlling diseases in humans by delivery of compositions comprising neuronal stem cells and exosomes of di encephalon lineage are disclosed. Also provided are pharmaceutical compositions tha...
|
|
WO/2021/185304A1 |
A method for preparing a long aliphatic chain diacid derivative. The method comprises: (1) performing a cyclization reaction on long aliphatic chain diacid, the long aliphatic chain diacid having a structure as shown in formula (A); (2) ...
|
|
WO/2021/185660A1 |
The present invention relates to means and methods that can be usedbased on a blood sample of a subject having sepsis, a subject suspected to have sepsis or a subject at risk to develop sepsis, to diagnose the subject with sepsis. The me...
|
|
WO/2021/180741A1 |
The present invention provides compounds and compositions containing reduced nicotinamide riboside for use in methods of prevention and/or treatment of pancreatic disease and/or conditions. In one embodiment of the invention, said compou...
|
|
WO/2021/182517A1 |
The purpose of the present invention is to provide a substance which is capable of expressing a protein, said protein having an amino acid sequence more closely similar to the amino acid sequence of a normal protein, while preventing the...
|
|
WO/2021/181436A1 |
The present invention relates to peroxiredoxin 6 or a synthetic analogue thereof for use as a hypoglycaemic agent, for example in the treatment of diabetes, such as type 1 diabetes mellitus and type 2 diabetes mellitus.
|
|
WO/2021/176026A1 |
Cosmetic compositions comprising a Gardenia fruit extract are provided.
|
|
WO/2021/170848A1 |
The present invention relates to an intervention strategy in the prevention or treatment of a subject having an inflammation-related disease such as Diabetes mellitus, autoimmune disease, inflammatory disease or cardiovascular disease. T...
|
|
WO/2021/172304A1 |
The main purpose of the present invention is to provide a new composition for enhancing estrogen secretion. A composition for enhancing estrogen secretion containing 4-methyl-2-phenyl-2-pentenal, 5-methyl-2-phenyl-2-hexenal, cacao, etc.
|
|
WO/2021/174165A1 |
The present disclosure features compounds of formula (l-a) and related compositions that, inter alia, modulate nucleic acid splicing e.g., splicing of a pre-mRNA, as well as methods of use thereof.
|
|
WO/2021/164718A1 |
The present invention provides a 2,6-disubstituted 1,2,4-triazine-3,5-dione compound having a structure represented by Formula I, or a pharmaceutically acceptable salt thereof. The above triazone derivative has a novel structure and exhi...
|
|
WO/2021/166899A1 |
The present invention provides a drug having excellent preventive, alleviating, and/or therapeutic effects against disease such as obesity and diabetes. Specifically, the present invention provides a gastric protease inhibitor-containing...
|
|
WO/2021/165316A1 |
The present invention relates to a dapagliflozin granulate composition, which is suitable for preparing capsules or tablets. It also relates to a pharmaceutical dosage form for oral administration which comprises such granulate. The inve...
|
|
WO/2021/163776A1 |
The present invention relates to subcutaneous implants comprising associations of active agents in one of the known types of collagen, or in other substances present in the subcutaneous cellular tissue, such as elastin, saturated fat, co...
|
|
WO/2021/164523A1 |
An Akkermansia muciniphila composition. Provided is a pharmaceutical composition, the pharmaceutical composition comprising Akkermansia muciniphila and metformin; and according to the mass of the pharmaceutical composition, the viable co...
|
|
WO/2021/163253A1 |
The present disclosure describes a method for treating or preventing an inflammatory ocular surface disease or disorder, such as ocular graft-versus-host disease, dry eye, meibomian gland disease, thyroid eye disease, blepharitis, Sjogre...
|
|
WO/2021/163273A1 |
The present invention relates generally to the use of a glucocorticoid receptor antagonist for treating cancer, specifically solid tumors and prostate cancer.
|
|
WO/2021/160188A1 |
Provided are a molecularly modified structure of an hGRH-like peptide and a dimer thereof, the dimer being made from two same modified hGHRH-like peptide monomers containing single cysteine molecules and connected by means of disulfide b...
|
|
WO/2021/158464A1 |
Melanocortin receptor-specific cyclic peptides of the formula where Xaa1 R1, R2, R3, R4, R7, R8, R9, R10, t, x and y are as defined in the specification, compositions and formulations including the peptides of the foregoing formula, and ...
|
|
WO/2021/156043A1 |
A pharmaceutical composition for adapted for oral administration comprising at least 10 % w/w native testosterone, at least 36% w/w sesame oil, at least 28% w/w propylene glycol monolaurate, at least 9 % w/w ethanol and at least 14 % w/w...
|
|
WO/2021/157625A1 |
Provided is a novel neovascularization device. The neovascularization device contains a neovascularization component and a polymer. The polymer optionally contains, for instance, at least one or more polyvinyl alcohol resins (A) select...
|
|
WO/2021/157626A1 |
Provided is a novel angiogenesis device. This angiogenesis device, which comprises an angiogenesis component and a polymer, is for inducing angiogenesis in a transplantation site of a cell- or tissue-containing device. The polymer may ...
|
|
WO/2021/158573A1 |
Various aspects of this patent document relate to bioactive compositions comprising anions that are converted into hydrophobic bioactive molecules either ex vivo prior to administration to a subject or in situ subsequent to administratio...
|
|
WO/2021/153635A1 |
The present invention provides a non-lamellar liquid crystal forming composition which is highly safe. The present invention relates to a non-lamellar liquid crystal forming composition that includes an amphipathic compound represented b...
|
